Document is current
Any future updates will be listed below
-
Authors
Seidizadeh, Omid http://orcid.org/0000-0002-6630-7879
Eikenboom, Jeroen C. J. http://orcid.org/0000-0002-3268-5759
Denis, Cécile V. http://orcid.org/0000-0001-5152-9156
Flood, Veronica H.
James, Paula
Lenting, Peter J.
Baronciani, Luciano
O’Donnell, James S.
Lillicrap, David
Peyvandi, Flora http://orcid.org/0000-0001-7423-9864
- License Information
-
More Information
Article History
Accepted: 27 June 2024
First Online: 25 July 2024
Competing interests
: F.P. reports participation at educational meetings of Takeda and Spark, and the advisory board of CSL Behring, Biomarin, Roche, Sanofi, and Sobi. C.V.D. and P.J.L. are co-inventors on patents related to von Willebrand factor and von Willebrand disease treatment and received research grants to the institute from Roche, Sanofi, Sobi and Biomarin. D.L. received research support from Biomarin, CSL Behring and Sanofi, and serves advisory roles for Biomarin, CSL Behring, Novo Nordisk, Pfizer and Sanofi. V.H.F. served on an advisory board for Octapharma. J.S.O. served on the speaker’s bureau for Baxter, Bayer, Novo Nordisk, Sobi, Boehringer Ingelheim, Leo Pharma, Takeda and Octapharma. He has also served on the advisory boards of Baxter, Sobi, Bayer, Octapharma, CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda and Pfizer. J.S.O. has also received research grant funding awards from 3M, Baxter, Bayer, Pfizer, Shire, Takeda and Novo Nordisk. P.J. received consultancy fees from Star/Vega, Band/Guardian, Biomarin and Roche. J.C.J.E. received a research grant from CSL Behring, all funds paid to the institute. O.S. and L.B. declare no competing interests.
